I share your concerns, but my take on InterCytex is pretty firm: a) either their management team is utterly incompetent or b) either they’re committing shareholder fraud with dead-end science.
If the science behind TRC needs improvement than a competent management team would gather the necessary resources to finish this project promptly. Statistically significant data along with before and after pictures would easily secure investor/shareholder dollars. On the other hand, if the science behind TRC is truly dead than management should desist their vague reports because that’s comparable to shareholder fraud. I know that sounds inflammatory, but where’s the data? where are the photos? They’ve been doing this long enough to have something tangible to show by now.
» True, but this would assume that the company has a good fundamental product
» to sell. As pointed out by several others, they dont seem to have that. Any
» company can come up with an IPO. there will be people who would take the
» risk and invest in something like this.
» But that doesnt prove anything about intercytex. On the other hand,
» private equity investors analyse their investments in much more detail
» (read: in follica). If 11M is invested as series B funding now, they should
» expect returns in 5 years. The returns im talking about are around 19X for
» seed funding (the original 5.5M) and 5X for series B funding (this varies
» from firm to firm, and on the market)
» Also, Intercytex’s results for phase 2 are all of 2 lines which say that
» density has increased. no pics, no real data. If I had money running on
» intercytex, Id pull out or turn my attention to the progress of their other
» products (which seem to show more promise)
Follica seem to have a struck the right balance between administration and research. I feel comfortable knowing they have a management team experienced bringing life-sciences to market. I’m also encouraged by their scientific/academic associations. Only time will tell where a competent team will take us (because we already know what incompetence yields)
» On an unrelated note, Follica’s modus operandi seems dangerously similar
» to that hedgehog agonist stuff from last year, which ended in failure cos
» the safety precautions could not be met. any thoughts ?